27. Neschadim, A., Medin, J.A. Engineered Thymidine-Active Deoxycytidine
Kinase for Bystander Killing of Malignant Cells. 2019. Methods Mol. Biol. 1895:149-163.
26. Lewis,
B.J.B., Leontyev, D., Neschadim, A., Blacquiere, M., Branch D.R. GM-CSF
and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role
for IL-11 cannot be ruled out. 2018. Clin Exp Immunol. 193(3):293-301.
25.
Resetca, D., Neschadim,
A., Medin, J.A. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to
Address Safety and Toxicity Concerns. J. of
Immunotherapy. 2016. 39(7):249-259. Review.
24.
Neschadim,
A., Kotra, L.P., and D.R. Branch. Small molecule phagocytosis inhibitors for immune cytopenias. Autoimmunity
Reviews. 2016. 15(8):843-7.
23.
Neschadim,
A., and D.R. Branch. Mouse
Models for Immune-mediated Platelet Destruction or Immune Thrombocytopenia
(ITP). Current Protocols in Immunology. 2016. 113:15.30.1-15.30.13.
22.
McCarthy, S.D.S., Sakac, D., Neschadim, A., Branch D.R. c-SRC
Protein Tyrosine Kinase Regulates Early HIV-1 Infection Post Entry. AIDS.
2016. 30(6):849-58
21. Neschadim, A., Summerlee, A.J.S., Silvertown, J.D. Targeting the Relaxin Hormonal Pathway in Prostate Cancer. International
Journal of Cancer. 2015. 137(10):2287-95. Review.
20.
Kozlowski, H.N., Lai, E.T.L., C-Havugimanac, P., White,
C., Emili, A., Sakac, D., Binnington, B., Neschadim,
A., McCarthy, S.D.S., Branch D.R. Extracellular
histones identified in crocodile blood inhibit in-vitro HIV-1 infection. AIDS.
2016. 30(13):2043-52.
19. Neschadim, A., and M.J.H.
Ratcliffe. Failure of Immunoglobulin
Heavy and Light Chain Association and Consequences to Apoptosis in the Bursa of
Fabricius. In preparation, Dept. of Immunology, 2016.
18. Sato,
T., Neschadim, A., Nakagawa, R., Yanagisawa,
T., Medin, J.A. Evaluation of Bystander
Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate
Kinase (TMPK)/AZT Enzyme-Prodrug Axis. Methods Mol. Biol. 2015. 1317: 55-67.
17. Neschadim, A., Branch, D.R.
Mouse Models of Autoimmune Diseases:
Immune Thrombocytopenia. Current Pharm. Design. 2014. 21(18):2487-97.
Review.
16.
Neschadim,
A., Pritzker, L.B., Pritzker, K.P.H., Branch, D., Summerlee, A.J.S., Trachtenberg, J., Silvertown, J.D. Relaxin receptor antagonist AT-001 synergizes
with docetaxel in androgen-independent prostate xenografts. Endocrine
Related Cancer. 2014. 21(3):459-71.
15.
Leontyev, D., Neschadim,
A., Branch. D.R. Cytokine profiles in
mouse models of experimental immune thrombocytopenia reveal a lack of inflammation
and differences in response to IVIg depending on the mouse strain.
Transfusion. 2014. 54(11):2871-9.
14.
Campbell, I.K., Miescher, S., Branch, D.R., Mott,
P.J., Lazarus, A.H., Han, D., Maraskovsky, E., Zuercher, A.W., Neschadim,
A., Leontyev, D., McKenzie, B.S., Käsermann, F. Therapeutic Effect of IVIG on Inflammatory
Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation
or Basophils. Journal of Immunology. 2014. 192(11):5031-8.
13. Purohit,
M.K., Chakka, S.K., Scovell, I., Neschadim, A., Salum, N., Bareau, M.C., Katsman, Y.,
Branch, D.R., Kotra, L.P. Structure-activity
relationships of pyrazole derivatives as potential therapeutics for I. Bioorganic
Medicinal Chemistry. 2014. 22(9):2739-52.
12. Sato,
T. *, Neschadim, A. *, Lavie, A., Yanagisawa,
T., Medin, J.A. The Engineered
Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis Offers Efficient Bystander
Cell Killing for Suicide Gene Therapy. PLoS One.
2013. 8(10): e78711. (*Equal
contributor).
11.
Scaife, M.D., Pacienza,
N.A., Au, B.C., Wang, J.C., Devine, S.P., Scheid, L., Lee, C-J., Lopez-Perez,
O., Neschadim, A., Fowler, D.H.,
Foley, R., Medin, J.A. Engineered Human Tmpk Fused with Truncated Cell Surface Markers: Versatile
Cell-Fate Control Safety Cassettes. Gene Therapy. 2013. 20(1): 24-34.
10.
Purohit, M., Scovell, I., Neschadim, A., Katsman,
Y., Branch, D., Kotra, L. Disulfide
Linked Pyrazole Derivatives Inhibit Phagocytosis of Opsonized blood cells. Bioorg. Med. Chem. Letters. 2013. 23(8): 2324-7.
9.
Neschadim,
A., Wang, J.C.M., Sato, T., Fowler, D.H., Lavie, A., Medin, J.A. Cell
Fate Control Gene Therapy based on Engineered Variants of Human Deoxycytidine
Kinase. Molecular Therapy. 2012. 20(5):1002-1013.
8. Neschadim, A., Wang, J.C.M.,
Lavie, A., Medin, J.A. Bystander killing of malignant cells via the delivery of novel
thymidine-active deoxycytidine kinase for suicide gene therapy of cancer.
Cancer Gene Therapy. 2012. 19(5): 320-327.
7.
Walia, J.S.*,
Neschadim, A.*, Lopez, O., Alayoubi, A., Fan, X., Madden, M., Lee, C-J., Cheung, F,
Jaffray, D., Levade, T., McCart, A.J., Medin, J.A. Supranormal Lysosomal Acid Ceramidase
Activity in Primates after Autologous Transplant of Lentivector-Transduced
Hematopoietic Cells. Human Gene Therapy. 2011. 22(6): 679-687. (*Equal contributor).
6.
Likar,
Y., Zurita, J., Shenker,
L., Cai, S., Neschadim, A., Medin,
J.A., Hricak, H., Ponomarev, V. A new pyrimidine-specific human reporter gene – mutated deoxycytidine
kinase suitable for PET imaging in patients treated with acycloguanosine-based
cytotoxic drugs. J. of Nuclear Medicine. 2010. 51(9):1395-1403.
5.
Silvertown, J.D., Neschadim,
A., Liu, H.N., Shannon, P., Walia, J.S., Kao, J.C.H., Robertson, J., Summerlee, A.J.S., and J.A. Medin. Relaxin-3 and receptors in the human and rhesus brain and reproductive
tissues. Regulatory Peptides. 2010. 159:44-53.
4. Scaife,
M.D., Neschadim, A., Fowler, D.H.,
Medin, J.A. Novel application of
lentiviral vectors towards treatment of graft-versus-host disease. Expert
Opinion in Biological Therapy. 2009. 9(6):749-61. Review.
3. Neschadim, A., McCart, J.A., Keating, A., Medin, J.A. A Roadmap to Safe, Efficient, and Stable Lentivirus-Mediated Gene
Therapy with Hematopoietic Cell Transplantation. BBMT. 2007.
13(12):1407-16. Review.
2. Sato,
T., Neschadim, A., Konrad, M., Lavie, A., Medin, J.A. Engineered
Human tmpk/AZT as a Novel Enzyme/Prodrug Axis for
Suicide Gene Therapy. Molecular Therapy. 2007. 15(5): 962-70.
1. Silvertown,
J.D., Symes J.C., Neschadim, A.,
Nonaka, T., Kao, J., Summerlee, A.J.S., Medin, J.A. Analog of H2 relaxin exhibits antagonistic
properties and impairs prostate tumor growth. FASEB J. 2007. 21(3): 754-65.
§
Neschadim,
A. Overcoming Tumor
Heterogeneity in Cancer Therapies, Immuno-Oncology Summit, Cambridge Healthtech Institute. Boston, MA. 2019. Oral Presentation.
§
Neschadim,
A. Overcoming
Cancer Heterogeneity with Tumor Microenvironment-Targeted Antibody-Drug
Conjugates: IMB-212 Program, The Essential Protein Engineering and Cell
Therapy Summit (PEGS). Boston, MA. 2019. Oral Presentation.
§
Neschadim,
A. The Experience
of Innovative Companies on the International Scene: Challenges and
Opportunities, International Innovation Conference 2014, CERBA. Panelist.
§
Neschadim,
A., Medin, J.A. Cell
Fate Control Gene Therapy for Applications in Cancer and Immune Disorders.
2011, International Forum on Cell Biotherapy. Chengdu, SC, China. Oral
Presentation.
§
Neschadim.
A. Regulatory
Oversight of Gene Therapy Clinical Trials: FDA Experience. Fuda Cancer Hospital, Jinan University School of Medicine.
Guangzhou, GD, China. 2011. Oral Presentation.
§
Neschadim.
A. Gene Therapy of
Monogenic Disorders with Lentiviral Vectors (LVs). Fuda
Cancer Hospital, Jinan University School of Medicine. Guangzhou, Guangdong,
China. 2011. Oral Presentation.
§
Neschadim,
A., Lavie, A., Sato, T.,
Fowler, D.H., Ponomarev, V., Medin, J.A. Next-Generation Lentiviral Cell Fate Control Gene Therapy Based on
Engineered Variants of Human Deoxycytidine Kinase. American
Society of Gene Therapy 13th Annual Meeting 2010. Oral Presentation.
§
Neschadim,
A., Lavie, A., Sato, T.,
Fowler, D.H., Ponomarev, V., Medin, J.A. Next-Generation
Lentiviral Cell Fate Control Gene Therapy based on Engineered Human deoxyCytidine Kinase. James Lepock Memorial Student
Symposium, Department of Medical Biophysics, UofT, 2010. Oral Presentation.
§ Neschadim, A., How to Enunciate the Importance of Research
Funding to the General Populace and the Government. Geneva Park Retreat,
Department of Medical Biophysics, UofT, 2009. Seminar.
§
Rotman Dean’s List, Bregman Scholar – 2016,
2017
§
Rotman Scholar, University of Toronto – 2016
§
Ontario Graduate Scholarship, Rotman School
of Management, UofT – 2016
§
CIHR Science to Business Scholarship, 2014 – 2016
§
Rotman Admissions Scholarship, 2014
§
MITACS – Enterprise Award, 2013
§
Ontario Centres of Excellence – First Job
Award, 2011
§
BioTalent Canada – Career Focus Award, 2011
§ CIHR Graduate Scholarship, Training Program in
Regenerative Medicine Award, 2005 – 2008, 2010
§ UofT SGS, Doctoral Thesis Completion Award, 2010
§ ASGCT, 13th Annual Meeting, Travel Award,
2010
§ Princess Margaret Hospital Foundation Graduate Fellowship in Cancer Research, OSOTF, 2006 – 2010
§ McCuaig-Throop Bursary, School of Grad. Studies, 2009
§ University of Toronto Open Fellowships, 2002 – 2008
§ Presentation Award, Day in Transplantation and
Immunology, MOT Program, TGH, UHN, 2008
§ Best Poster, Langdon Hall Gene Therapy Meeting, 2006
§ Travel Award, XVI International AIDS Conference, 2006
§ Reuben Wells Leonard Scholarship in Physics, 2002
§ Robert and Jean Hadgraft
Scholarship in Chemistry, Dept. of Chemistry, University of Toronto, 2002
§ OSOTF (Richard Ivey Foundation) Summer Research Award,
Dept. of Chemistry, University of Toronto, 2001
§ William Robert Luscombe Bursary, UofT, 2001
§ Dr. James A. & Connie P. Dickson Scholarship in
the Sciences and Mathematics, University of Toronto, 2000
§ University of Toronto Dean's List, 2000, 2001
